Subtype
High Grade Astrocytic Tumor
CI-CAN-00005503Explore in graph →
495 active trials2 approved drugs51 evidence items
- NCIt
- C102897
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005503Explore in graph →
Clinical trials
1,778 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (283)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00268385 | Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas | active not recruiting | Phase 1 | 83 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07762716 | Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy | not yet recruiting | Phase 1 / Phase 2 | 10 | BreakBio CorpINDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04903795 | BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma(BRiTE) | recruiting | Phase 1 | 18 | Mustafa Khasraw, MBChB, MD, FRCP, FRACPOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06632236 | 5G-EMERALD: Amivantamab in Malignant Brain Tumours(5G-EMERALD) | active not recruiting | Phase 1 | 12 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06894979 | Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma | active not recruiting | Phase 1 | 54 | Children's Oncology GroupNETWORK | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06344130 | Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma | recruiting | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Aug 14, 2026 | clinicaltrials |
| NCT03389802 | Phase I Study of APX005M in Pediatric Central Nervous System Tumors | completed | Phase 1 | 32 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05450744 | 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)(IPAX-2) | active not recruiting | Phase 1 | 12 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 3 | Aug 13, 2026 | clinicaltrials |
| NCT06186401 | Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells | recruiting | Phase 1 | 20 | Hideho Okada, MD, PhDOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06614855 | A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma | active not recruiting | Phase 1 | 12 | James Markert, MDOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06161519 | PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications | recruiting | Phase 1 / Phase 2 | 146 | National Cancer Institute (NCI)NIH | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07544992 | Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas | recruiting | Phase 1 | 24 | City of Hope Medical CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04197934 | WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases | active not recruiting | Phase 1 | 56 | Mayo ClinicOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07501559 | A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM) | recruiting | Phase 1 / Phase 2 | 40 | Jecho Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07733674 | Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)(RMX-VH) | recruiting | Phase 1 | 20 | Radiomedix, Inc.INDUSTRY | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07751744 | Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma | not yet recruiting | Phase 1 / Phase 2 | 113 | Jubilant Therapeutics Inc.INDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT01837862 | A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | active not recruiting | Phase 1 / Phase 2 | 10 | Julie KrystalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05565118 | Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression | recruiting | Phase 1 | 10 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT03643549 | Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17)(BORTEM-17) | recruiting | Phase 1 / Phase 2 | 63 | Haukeland University HospitalOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07739017 | OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma(OPAL) | not yet recruiting | Phase 1 | 54 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04555577 | Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma | active not recruiting | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07464925 | A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma | recruiting | Phase 1 | 30 | Tetragon Biosciences LtdINDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT02208362 | Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma | active not recruiting | Phase 1 | 65 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06973096 | CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy | active not recruiting | Phase 1 | 9 | University of PennsylvaniaOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06672575 | A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04900792 | A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma(XACT-Fe-GBM-01) | active not recruiting | Phase 1 | 16 | Bryan AllenOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT03423628 | A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer | active not recruiting | Phase 1 | 159 | AstraZenecaINDUSTRY | 3 | Jul 17, 2026 | clinicaltrials |
| NCT05660369 | CARv3-TEAM-E T Cells in Glioblastoma | recruiting | Phase 1 | 21 | Marcela V. Maus, M.D.,Ph.D.OTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05835687 | Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors | active not recruiting | Phase 1 | 29 | St. Jude Children's Research HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05698199 | Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM) | completed | Phase 1 | 10 | Immunomic Therapeutics, Inc.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06455189 | Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas | withdrawn | Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05627323 | CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma | terminated | Phase 1 | 1 | Chimeric TherapeuticsINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06815029 | Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma | recruiting | Phase 1 | 27 | City of Hope Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06157541 | T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma(TCaP) | active not recruiting | Phase 1 / Phase 2 | 58 | Queensland Institute of Medical ResearchOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT04573140 | A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)(PNOC020) | recruiting | Phase 1 | 28 | University of FloridaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07468136 | Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas | recruiting | Phase 1 / Phase 2 | 33 | Mayo ClinicOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04678648 | A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies | recruiting | Phase 1 | 134 | RasCal Therapeutics, Inc.INDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05590689 | Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor(ALA-RDTinGBM) | recruiting | Phase 1 / Phase 2 | 34 | Universität MünsterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07392957 | Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 54 | Washington University School of MedicineOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07541781 | Sitagliptin in Recurrent/Progressive Grade 4 Glioma | recruiting | Phase 1 | 45 | Kailin Yang, MD, PhDOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04323046 | Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults | active not recruiting | Phase 1 | 9 | Sabine Mueller, MD, PhDOTHER | 2 | Jun 15, 2026 | clinicaltrials |
| NCT07346144 | Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma(ADePT) | recruiting | Phase 1 / Phase 2 | 68 | Trogenix ltdINDUSTRY | 2 | Jun 12, 2026 | clinicaltrials |
| NCT07422363 | Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma | not yet recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 0 | Jun 12, 2026 | clinicaltrials |
| NCT07643870 | Human ADME Study of [14C]-AZD1390 | not yet recruiting | Phase 1 | 8 | AstraZenecaINDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03866109 | A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT(TEM-GBM) | terminated | Phase 1 / Phase 2 | 25 | Genenta ScienceINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04732065 | ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors(PNOC023) | recruiting | Phase 1 | 208 | Sabine Mueller, MD, PhDOTHER | 3 | Jun 11, 2026 | clinicaltrials |
| NCT05283330 | Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors | recruiting | Phase 1 | 48 | Orano Med Theranostics, SASINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06622434 | New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study(NAVIG-1) | recruiting | Phase 1 / Phase 2 | 35 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05053880 | A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme | active not recruiting | Phase 1 / Phase 2 | 48 | Accendatech USA Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07635173 | SM-1 Combined With Temozolomide in Subjects With Refractory or Recurrent High-Grade Gliomas | completed | Phase 1 | 35 | Shenzhen Zhenxing Medical Technology Co., LtdOTHER | 1 | Jun 9, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 20, 2026source: clinicaltrials